Allogene Therapeutics Inc. (ALLO:NSD) Analysts rate as a Buy, $21 target

STA Research
by: STA Research
Allogene Therapeutics Inc.
ALLO Stock Forecast & Price:

Based on the Allogene Therapeutics Inc. stock forecasts from 7 analysts, the average analyst target price for Allogene Therapeutics Inc is USD 20.89 over the next 12 months. Allogene Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Allogene Therapeutics Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Allogene Therapeutics Inc’s stock price was USD 16.20Allogene Therapeutics Inc’s stock price has changed by +18.94% over the past week, +34.66% over the past month and -26.46% over the last year.

A clinical-stage immuno-oncology business called Allogene Therapeutics, Inc. creates and sells genetically modified allogeneic T cell treatments for the treatment of cancer. Additionally, it has a strategic partnership agreement for the preclinical and clinical examination of potential allogeneic CAR T cell product candidates with The University of Texas MD Anderson Cancer Center. The business was established in 2017 and has its main office in South San Francisco, California. 210 East Grand Avenue, South San Francisco, California, 94080, USA


What we like:

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.


What we don’t like:

Poor risk-adjusted returns

This company is delivering below median risk-adjusted returns to its peers. Even if it is outperforming on returns, the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peer’s median on a price-to-book value basis.

Negative cash flow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.


Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.